AP3491A - Triazolopyridines - Google Patents

Triazolopyridines

Info

Publication number
AP3491A
AP3491A AP2013007182A AP2013007182A AP3491A AP 3491 A AP3491 A AP 3491A AP 2013007182 A AP2013007182 A AP 2013007182A AP 2013007182 A AP2013007182 A AP 2013007182A AP 3491 A AP3491 A AP 3491A
Authority
AP
ARIPO
Prior art keywords
triazolopyridines
Prior art date
Application number
AP2013007182A
Other languages
English (en)
Other versions
AP2013007182A0 (en
Inventor
Hans Briem
Philip Lienau
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AP2013007182A0 publication Critical patent/AP2013007182A0/xx
Application granted granted Critical
Publication of AP3491A publication Critical patent/AP3491A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2013007182A 2011-04-21 2012-04-16 Triazolopyridines AP3491A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27
PCT/EP2012/056914 WO2012143329A1 (en) 2011-04-21 2012-04-16 Triazolopyridines

Publications (2)

Publication Number Publication Date
AP2013007182A0 AP2013007182A0 (en) 2013-10-31
AP3491A true AP3491A (en) 2015-12-31

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007182A AP3491A (en) 2011-04-21 2012-04-16 Triazolopyridines

Country Status (39)

Country Link
US (1) US20140120087A1 (ar)
EP (1) EP2699575B1 (ar)
JP (1) JP5989091B2 (ar)
KR (1) KR20140025470A (ar)
CN (1) CN103608350B (ar)
AP (1) AP3491A (ar)
AR (1) AR086191A1 (ar)
AU (1) AU2012244859B2 (ar)
CA (1) CA2833657A1 (ar)
CL (1) CL2013003044A1 (ar)
CO (1) CO6801751A2 (ar)
CR (1) CR20130539A (ar)
CY (1) CY1116439T1 (ar)
DK (1) DK2699575T3 (ar)
DO (1) DOP2013000244A (ar)
EA (1) EA023766B1 (ar)
EC (1) ECSP13013011A (ar)
ES (1) ES2539265T3 (ar)
GT (1) GT201300254A (ar)
HR (1) HRP20150517T1 (ar)
HU (1) HUE025496T2 (ar)
IL (1) IL228704A0 (ar)
JO (1) JO3040B1 (ar)
MA (1) MA35049B1 (ar)
ME (1) ME02143B (ar)
MX (1) MX348783B (ar)
MY (1) MY164939A (ar)
PE (1) PE20141351A1 (ar)
PH (1) PH12013502169A1 (ar)
PL (1) PL2699575T3 (ar)
PT (1) PT2699575E (ar)
RS (1) RS54044B1 (ar)
SA (1) SA112330466B1 (ar)
SG (1) SG194003A1 (ar)
SI (1) SI2699575T1 (ar)
TW (1) TWI558703B (ar)
UY (1) UY34034A (ar)
WO (1) WO2012143329A1 (ar)
ZA (1) ZA201308707B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
EP2825540B1 (en) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
BR112015000308A2 (pt) * 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9670202B2 (en) * 2013-06-07 2017-06-06 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
MX2015017011A (es) * 2013-06-10 2016-04-25 Bayer Pharma AG Compuestos nuevos para el tratamiento del cancer.
US20160128988A1 (en) * 2013-06-11 2016-05-12 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
US9586958B2 (en) 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
DK3283642T3 (da) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Prognostiske biomarkører til ttk-hæmmerbaseret kemoterapi
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2020215094A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
WO2011063908A1 (en) * 2009-11-30 2011-06-03 Bayer Schering Pharma Aktiengesellschaft Triazolopyridines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU2005274277A1 (en) 2004-08-17 2006-02-23 Galderma Research & Development, S.N.C. Novel biaromatic compounds which activate receptors of PPAR type and their use in cosmetic or pharmaceutical compositions
AU2008277628B2 (en) * 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
CN103298814A (zh) 2007-08-23 2013-09-11 阿斯利康(瑞典)有限公司 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (en) * 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
EA201101188A1 (ru) * 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
WO2011063908A1 (en) * 2009-11-30 2011-06-03 Bayer Schering Pharma Aktiengesellschaft Triazolopyridines

Also Published As

Publication number Publication date
JP2014511887A (ja) 2014-05-19
ME02143B (me) 2015-10-20
KR20140025470A (ko) 2014-03-04
UY34034A (es) 2012-11-30
NZ616456A (en) 2015-09-25
PT2699575E (pt) 2015-07-29
CA2833657A1 (en) 2012-10-26
CR20130539A (es) 2013-12-04
DK2699575T3 (da) 2015-06-22
CN103608350B (zh) 2015-11-25
AU2012244859A1 (en) 2013-10-31
AP2013007182A0 (en) 2013-10-31
GT201300254A (es) 2015-09-01
SG194003A1 (en) 2013-11-29
CY1116439T1 (el) 2017-02-08
JP5989091B2 (ja) 2016-09-07
RS54044B1 (sr) 2015-10-30
HRP20150517T1 (hr) 2015-06-19
CN103608350A (zh) 2014-02-26
MY164939A (en) 2018-02-15
US20140120087A1 (en) 2014-05-01
PE20141351A1 (es) 2014-11-01
EA201301181A1 (ru) 2014-08-29
CO6801751A2 (es) 2013-11-29
WO2012143329A1 (en) 2012-10-26
HK1190398A1 (zh) 2014-07-04
MA35049B1 (fr) 2014-04-03
CL2013003044A1 (es) 2014-05-02
EA023766B1 (ru) 2016-07-29
TW201245194A (en) 2012-11-16
ECSP13013011A (es) 2013-12-31
PH12013502169A1 (en) 2014-01-13
SI2699575T1 (sl) 2015-10-30
ES2539265T3 (es) 2015-06-29
EP2699575B1 (en) 2015-03-25
ZA201308707B (en) 2016-07-27
AR086191A1 (es) 2013-11-27
MX2013012289A (es) 2013-11-21
AU2012244859B2 (en) 2017-06-08
PL2699575T3 (pl) 2015-08-31
JO3040B1 (ar) 2016-09-05
EP2699575A1 (en) 2014-02-26
TWI558703B (zh) 2016-11-21
IL228704A0 (en) 2013-12-31
SA112330466B1 (ar) 2015-09-28
MX348783B (es) 2017-06-28
DOP2013000244A (es) 2014-03-16
HUE025496T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
DK3505720T3 (en) Cementering under styret tryk
DK3798230T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
AP3491A (en) Triazolopyridines
EP2755962A4 (en) AZAINDAZOLES
EP2715659A4 (en) ABOUT FEED
EP2723631A4 (en) QUADFOILER
EP2776444A4 (en) dihydropteridinones
EP2695208A4 (en) MICRO-THERMOCOUPLE
IL227377A0 (en) Combinations
GB201109024D0 (en) Can
GB201101727D0 (en) Obuoy
GB201100001D0 (en) TidySqueeze2
AU5026P (en) Goldstrike Agapanthus inapertus
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5031P (en) BESYS Beschorneria yuccoides
AU5171P (en) Sunparamiho Mandevilla xamabilis
GB201109627D0 (en) Easy clear
AU340282S (en) Can
GB201115238D0 (en) Pit-stop easy
AP00723S1 (en) Autorickshaw
GB201100168D0 (en) SecuriPad
GB201102977D0 (en) Cyclobuggy
GB201100055D0 (en) Evac-sac
GB201102443D0 (en) Atompower